| 19.28 1.21 (6.7%) | 07-31 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 22.53 |
1-year : | 26.31 |
| Resists | First : | 19.29 |
Second : | 22.53 |
| Pivot price | 15.78 |
|||
| Supports | First : | 16.25 |
Second : | 14.38 |
| MAs | MA(5) : | 16.73 |
MA(20) : | 15.83 |
| MA(100) : | 14.95 |
MA(250) : | 11.8 |
|
| MACD | MACD : | 0.5 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 79.3 |
D(3) : | 57 |
| RSI | RSI(14): 78.6 |
|||
| 52-week | High : | 19.29 | Low : | 7.92 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ANIK ] has closed It is unclear right now based on current values. 140.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 19.3 - 19.36 | 19.36 - 19.42 |
| Low: | 17.74 - 17.81 | 17.81 - 17.89 |
| Close: | 19.16 - 19.26 | 19.26 - 19.38 |
Anika Therapeutics, Inc. is a company dedicated to joint preservation, innovating and providing early intervention orthopedic care across the globe, including the United States and Europe. Their core focus areas include osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and advanced bone-preserving joint technologies. All of Anika's products are developed, manufactured, and commercialized utilizing their proprietary hyaluronic acid (HA) technology platform. Their comprehensive product lines feature an OA pain management family, which includes established treatments like Monovisc, Orthovisc, Cingal, and Hyvisc, all designed to alleviate discomfort from osteoarthritis. The company's joint preservation and restoration offerings are extensive, comprising approximately 150 bone-sparing joint technology products, alongside solutions for sports medicine soft tissue repair and orthopedic regenerative therapies. Furthermore, Anika leverages its HA expertise in a non-orthopedic product family, developing applications such as adhesion barriers, advanced wound care products, ophthalmic solutions, and ear, nose, and throat treatments. Anika Therapeutics, Inc. was established in 1983 and is based in Bedford, Massachusetts.
Sun, 02 Aug 2026
Anika Therapeutics (ANIK) Stock Fair Value Rises After Q2 Beat And Higher Guidance - Yahoo Finance UK
Fri, 31 Jul 2026
Vanguard Capital Management (ANIK) discloses 4.95% beneficial stake in Anika Therapeutics - Stock Titan
Fri, 31 Jul 2026
Anika Therapeutics (ANIK) Stock Jumps As Profit Returns Sharpen Margin Focus - simplywall.st
Thu, 30 Jul 2026
Biotech Stocks At 52-Week Highs - ANIK & CHE Rise With Q2 Results, ICUI, NBIX, RPRX - RTTNews
Wed, 29 Jul 2026
Anika Therapeutics Inc (ANIK) Q2 2026 Earnings Call Highlights: Record Revenue and Margin ... - Yahoo Finance
Wed, 29 Jul 2026
Is Anika Therapeutics Inc (ANIK) On The Rise After Q2 Earnings B - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 13 (M) |
| Shares Float | 11 (M) |
| Held by Insiders | 6.4 (%) |
| Held by Institutions | 94.7 (%) |
| Shares Short | 350 (K) |
| Shares Short P.Month | 425 (K) |
| EPS | -0.8 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 10.02 |
| Profit Margin | -9.6 % |
| Operating Margin | -13.2 % |
| Return on Assets (ttm) | -3.6 % |
| Return on Equity (ttm) | -7.9 % |
| Qtrly Rev. Growth | 13.1 % |
| Gross Profit (p.s.) | 5.11 |
| Sales Per Share | 8.73 |
| EBITDA (p.s.) | -0.4 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 6 (M) |
| Levered Free Cash Flow | 7 (M) |
| PE Ratio | -24.41 |
| PEG Ratio | 3.5 |
| Price to Book value | 1.92 |
| Price to Sales | 2.2 |
| Price to Cash Flow | 39.66 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|